International Journal of Spectroscopy / 2009 / Article / Tab 1

Research Article

Calculation and Comparison of Energy Interaction and Intensity Parameters for the Interaction of Nd(III) with DL-Valine, DL-Alanine and -Alanine in Presence and Absence of / in Aqueous and Different Aquated Organic Solvents Using 4f-4f Transition Spectra as Probe

Table 1

Computed value of energy interaction parameters—Slater Condon (cm-1), Spin Orbit Interaction (cm-1), Nephelauxetic ratio ( ), bonding (b1/2), and covalency ( ) parameters of Nd(III), Nd(III) : amino acid (1 : 1), Nd(III) : amino acid : Ca(II) (1 : 1 : 1), and Nd(III) : amino acid : Zn(II) (1 : 1 : 1) in aqueous and different aquated organic solvents (50 : 50) at pH4.

SystemF2F4F6 b1/2

1. Solvent—Water
Ligand—DL-valine
Nd(III)328.7748.225.20951.551.02200.10482.1527
Nd(III): L328.2148.215.19951.541.02700.11612.6260
Nd(III) : L : Ca(II)327.9448.195.17950.011.02930.12112.8498
Nd(III) : L : Zn(II)327.8348.125.17950.001.03030.12312.9400
Ligand—DL-alanine
Nd(III) : L327.6848.605.25961.651.03080.12422.9904
Nd(III) : L : Ca(II)327.5548.695.24961.621.03230.12703.1258
Nd(III) : L : Zn(II)327.4948.695.23961.601.03300.12843.1928
Ligand— -alanine
Nd(III) : L327.8748.675.24959.591.02950.12152.8672
Nd(III) : L : Ca(II)327.8448.665.23959.571.02980.12212.8958
Nd(III) : L: Zn(II)327.8248.655.22959.551.03010.12262.9172
2. Solvent—Methanol
Ligand—DL-valine
Nd(III)330.1248.105.13928.151.00680.05830.6746
Nd(III) : L330.0248.095.13928.141.00760.06180.7587
Nd(III) : L : Ca(II)330.0048.075.12928.131.00830.06460.8263
Nd(III) : L : Zn(II)329.9548.055.10928.121.01130.07521.1176
Ligand—DL-alanine
Nd(III) : L330.0748.095.12928.541.00770.06230.7711
Nd(III) : L : Ca(II)330.0048.085.10928.521.01170.07661.1588
Nd(III) : L : Zn(II)329.9848.085.10928.491.01190.07721.1786
Ligand— -alanine
Nd(III) : L330.0348.145.12927.401.00800.06340.7973
Nd(III) : L : Ca(II)329.9948.135.10927.391.00910.06730.8988
Nd(III) : L: Zn(II)329.9248.125.09927.301.01250.07901.2333
3. Solvent—MeCN
Ligand—DL-valine
Nd(III)330.1148.135.13928.061.00690.05870.6854
Nd(III) : L330.0848.125.11928.021.00780.06230.7709
Nd(III) : L : Ca(II)330.0748.125.10928.011.00790.06290.7846
Nd(III) : L : Zn(II)330.0648.115.05927.951.00800.06330.7955
Ligand—DL-alanine
Nd(III) : L329.9448.185.12927.851.00830.06450.8250
Nd(III) : L : Ca(II)329.9248.145.11927.831.00790.06280.7820
Nd(III) : L : Zn(II)329.9148.125.09927.801.00860.06550.8501
Ligand— -alanine
Nd(III) : L329.9848.205.12928.111.00810.06380.8085
Nd(III) : L : Ca(II)329.9748.195.11928.101.00830.06420.8184
Nd(III) : L: Zn(II)329.9548.175.10928.071.00840.06500.8304
4. Solvent—DMF
Ligand—DL-valine
Nd(III)329.9948.205.14929.451.00820.06400.8122
Nd(III) : L329.9648.115.12929.431.01130.07531.1216
Nd(III) : L : Ca(II)329.2948.615.11929.401.01770.09411.7383
Nd(III) : L : Zn(II)329.2748.615.10929.351.01800.09501.7726
Ligand—DL-alanine
Nd(III) : L329.7748.155.14933.421.01310.08091.2916
Nd(III) : L : Ca(II)329.2148.125.10933.361.01820.09531.7848
Nd(III) : L : Zn(II)329.2148.085.05933.301.01830.09561.7933
Ligand— -alanine
Nd(III) : L329.8048.125.14934.581.01300.08051.2797
Nd(III) : L : Ca(II)329.2648.105.12934.551.01820.09541.7894
Nd(III) : L: Zn(II)329.2548.615.21934.531.01830.09561.7952
5. Solvent—Dioxane
Ligand—DL-valine
Nd(III)330.1548.145.13927.181.00640.05670.6372
Nd(III) : L330.1148.145.12927.161.00690.05910.6928
Nd(III) : L : Ca(II)330.0948.125.11927.131.00710.05960.7050
Nd(III) : L : Zn(II)330.0248.105.10927.121.00820.06420.8181
Ligand—DL-alanine
Nd(III) : L330.0648.115.12928.541.00740.06270.7793
Nd(III) : L : Ca(II)330.0448.105.11928.501.00810.06370.8061
Nd(III) : L : Zn(II)330.0248.135.13928.491.00830.06420.8186
Ligand— -alanine
Nd(III) : L330.0848.125.13929.141.00810.06360.8026
Nd(III) : L : Ca(II)330.0648.115.12929.131.00830.06420.8184
Nd(III) : L : Zn(II)330.0448.105.11929.101.00850.06510.8405

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.